Suzhou Degen Biomedical

Suzhou Degen Biomedical is a Chinese biotechnology company that serves as the primary research and development arm of Jiangsu Degen Pharmaceutical. Based in the Suzhou Industrial Park, the company focuses on the discovery and clinical development of innovative small molecule therapeutics for metabolic disorders and oncology. Its most advanced program, DG-001 (also known as VT-101), is a novel GPR40 agonist currently in Phase 2 clinical trials for the treatment of Type 2 Diabetes. The company's pipeline also includes several other candidates targeting SGLT2 and DPP-4, as well as early-stage programs in oncology. Suzhou Degen leverages its strong ties to the Shanghai Institute of Materia Medica to accelerate its drug discovery efforts and transition toward an innovation-led business model. The company integrates advanced medicinal chemistry and pharmacological screening to build a robust pipeline of proprietary therapeutic agents.